WO2007006926A3 - Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk - Google Patents

Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk Download PDF

Info

Publication number
WO2007006926A3
WO2007006926A3 PCT/FR2006/001619 FR2006001619W WO2007006926A3 WO 2007006926 A3 WO2007006926 A3 WO 2007006926A3 FR 2006001619 W FR2006001619 W FR 2006001619W WO 2007006926 A3 WO2007006926 A3 WO 2007006926A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicaments
alkyl
novel
preparation
pharmaceutical compositions
Prior art date
Application number
PCT/FR2006/001619
Other languages
English (en)
Other versions
WO2007006926A2 (fr
Inventor
Jean Wagnon
Jean-Flaubert Nguefack
Samir Jegham
Michael Bosch
Monsif Bouaboula
Pierre Casellas
Bernard Tonnerre
Jacob-Alsboek Olsen
Serge Mignani
Original Assignee
Sanofi Aventis
Jean Wagnon
Jean-Flaubert Nguefack
Samir Jegham
Michael Bosch
Monsif Bouaboula
Pierre Casellas
Bernard Tonnerre
Jacob-Alsboek Olsen
Serge Mignani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507370A external-priority patent/FR2888239B1/fr
Priority claimed from FR0511950A external-priority patent/FR2893941B1/fr
Priority to NZ564872A priority Critical patent/NZ564872A/en
Priority to EP06778795A priority patent/EP1904479A2/fr
Priority to JP2008520910A priority patent/JP2009501711A/ja
Priority to MX2008000574A priority patent/MX2008000574A/es
Priority to AU2006268531A priority patent/AU2006268531A1/en
Application filed by Sanofi Aventis, Jean Wagnon, Jean-Flaubert Nguefack, Samir Jegham, Michael Bosch, Monsif Bouaboula, Pierre Casellas, Bernard Tonnerre, Jacob-Alsboek Olsen, Serge Mignani filed Critical Sanofi Aventis
Priority to EA200800285A priority patent/EA200800285A1/ru
Priority to BRPI0613452-1A priority patent/BRPI0613452A2/pt
Priority to CA002614597A priority patent/CA2614597A1/fr
Publication of WO2007006926A2 publication Critical patent/WO2007006926A2/fr
Publication of WO2007006926A3 publication Critical patent/WO2007006926A3/fr
Priority to TNP2007000471A priority patent/TNSN07471A1/en
Priority to EC2007008064A priority patent/ECSP078064A/es
Priority to IL188494A priority patent/IL188494A0/en
Priority to US11/971,389 priority patent/US20080269170A1/en
Priority to NO20080456A priority patent/NO20080456L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne les produits de formule (I) dans laquelle R2, R3 et R4 représentent l'un hydrogène et les autres hydrogène, halogène, alkyle ou alcoxy; R5 représente hydrogêne ou halogène; Rl représente hydrogène, cycloalkyle, alkyle, alkényle ou alkynyle, tous éventuellement substitués ; A représente simple liaison ou -CH2-CO-NR6- avec R6 est choisi parmi les valeurs de Rl; le cycle renfermant Y (ou cycle (Y) ) ayant 4 à 8 chaînons avec Y représente O, S, SO, SO2 , N-R7 (cycle (Y) pouvant renfermant un pont carboné) , C=O ou son dioxolanne, CF2 , CH-0R8, CH-NR8R9 ; et R7 représente hydrogène, cycloalkyle, alkyle, CH2 -alkényle ou CH2- alkynyle, éventuellement substitués ; R8 représente hydrogène, alkyle, cycloalkyle ou hétérocycloalkyle éventuellement substitués,- ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments notamment comme inhibiteurs de IKK.
PCT/FR2006/001619 2005-07-11 2006-07-06 Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk WO2007006926A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BRPI0613452-1A BRPI0613452A2 (pt) 2005-07-11 2006-07-06 derivados de 2,4-dianilino pirimidinas, o respectivo preparo, a tìtulo de medicamentos, composições farmacêuticas e notadamente como inibidores de ikk
CA002614597A CA2614597A1 (fr) 2005-07-11 2006-07-06 Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EA200800285A EA200800285A1 (ru) 2005-07-11 2006-07-06 Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
EP06778795A EP1904479A2 (fr) 2005-07-11 2006-07-06 Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
JP2008520910A JP2009501711A (ja) 2005-07-11 2006-07-06 新規２，４−ジアニリノピリミジン誘導体、その調製、医薬、医薬組成物としての、特に、ｉｋｋ阻害剤としてのそれらの使用
MX2008000574A MX2008000574A (es) 2005-07-11 2006-07-06 Nuevos derivados de 2,4-dianilinopirimidinas, la preparacion de los mismos, su uso como medicamentos, composiciones farmaceuticas y, en particular, como inhibidores ikk.
AU2006268531A AU2006268531A1 (en) 2005-07-11 2006-07-06 Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as IKK inhibitors
NZ564872A NZ564872A (en) 2005-07-11 2006-07-06 Novel 2,4-dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
TNP2007000471A TNSN07471A1 (en) 2005-07-11 2007-12-14 Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
EC2007008064A ECSP078064A (es) 2005-07-11 2007-12-28 NUEVOS DERIVADOS de 2,4-DIANILINOPIRIMIDINAS, SU PREPARACIÓN, COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y PRINCIPALMENTE COMO INHIBIDORES DE IKK
IL188494A IL188494A0 (en) 2005-07-11 2007-12-30 Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
US11/971,389 US20080269170A1 (en) 2005-07-11 2008-01-09 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors
NO20080456A NO20080456L (no) 2005-07-11 2008-01-24 Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0507370A FR2888239B1 (fr) 2005-07-11 2005-07-11 Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR0507370 2005-07-11
FR0511950A FR2893941B1 (fr) 2005-11-25 2005-11-25 Nouveaux derives de 2,4-dianilinopyridines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR0511950 2005-11-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/971,389 Continuation US20080269170A1 (en) 2005-07-11 2008-01-09 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors

Publications (2)

Publication Number Publication Date
WO2007006926A2 WO2007006926A2 (fr) 2007-01-18
WO2007006926A3 true WO2007006926A3 (fr) 2007-03-22

Family

ID=37606288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/001619 WO2007006926A2 (fr) 2005-07-11 2006-07-06 Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk

Country Status (17)

Country Link
US (1) US20080269170A1 (fr)
EP (1) EP1904479A2 (fr)
JP (1) JP2009501711A (fr)
KR (1) KR20080027832A (fr)
AU (1) AU2006268531A1 (fr)
BR (1) BRPI0613452A2 (fr)
CA (1) CA2614597A1 (fr)
CR (1) CR9602A (fr)
EA (1) EA200800285A1 (fr)
EC (1) ECSP078064A (fr)
IL (1) IL188494A0 (fr)
MA (1) MA29649B1 (fr)
MX (1) MX2008000574A (fr)
NO (1) NO20080456L (fr)
NZ (1) NZ564872A (fr)
TN (1) TNSN07471A1 (fr)
WO (1) WO2007006926A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
KR20080064953A (ko) * 2005-10-13 2008-07-10 모르포켐 악티엥게셀샤프트 퓌르 콤비나토리셰 케미 항균 활성을 갖는 5-퀴놀린 유도체
WO2007120980A2 (fr) 2006-02-17 2007-10-25 Rigel Pharmaceuticals, Inc. Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8219697B2 (en) * 2006-05-17 2012-07-10 Oracle International Corporation Diameter protocol and SH interface support for SIP server architecture
EP2222647B1 (fr) 2006-10-23 2015-08-05 Cephalon, Inc. Dérives bicycliques fusionnes de 2,4-diaminopyrimidine utilises comme inhibiteurs de alk et c-met
FR2911140B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911137B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2,4-dianilinopyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2919869B1 (fr) * 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009143389A1 (fr) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Dérivés phosphorés servant d'inhibiteurs de kinase
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2013205506B2 (en) * 2008-05-21 2016-04-21 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
WO2012073254A1 (fr) * 2010-11-29 2012-06-07 Hetero Research Foundation Procédé de préparation de pazopanib à l'aide d'un nouvel intermédiaire
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
MX360404B (es) 2011-05-04 2018-10-31 Ariad Pharma Inc Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
WO2013169401A1 (fr) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Composés pour inhiber la prolifération cellulaire dans les cancers induits par l'egfr
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
EP3152557A4 (fr) 2014-06-09 2017-12-13 Biometry Inc. Bandelette réactive à faible coût et procédé pour mesurer un analyte
CN109715067B (zh) 2016-07-19 2022-05-17 生物统计股份有限公司 使用批量可校准测试条测量分析物的方法和系统
AU2018240172C1 (en) 2017-03-20 2019-10-24 Novo Nordisk Health Care Ag Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
CN113226356A (zh) 2018-09-19 2021-08-06 福马治疗股份有限公司 活化丙酮酸激酶r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
WO2023212574A1 (fr) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions et méthodes de modulation de l'activité rythmique de cardiomyocytes de stimulateur cardiaque

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039101A1 (fr) * 1998-12-24 2000-07-06 Astrazeneca Ab Composes de pyrimidine
WO2001064654A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab Composes de pyrimidine
WO2003066601A1 (fr) * 2002-02-08 2003-08-14 Smithkline Beecham Corporation Composes de pyrimidine
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
US20040063705A1 (en) * 2001-08-22 2004-04-01 Jean-Christophe Harmange Substituted pyrimidinyl derivatives and methods of use
WO2005013996A2 (fr) * 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. Composes de 2,4-pyrimidinediamine et leurs utilisations comme agents antiproliferants
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0720032A2 (pt) * 2006-12-13 2013-12-17 Gilead Sciences Inc Composto e sais farmaceuticamente aceitáveis dos mesmos, processo, formulação de aerossol, método para a prevenção e tratamento de inflamação pulmonar ou broncoconstrição, e, uso de um composto.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039101A1 (fr) * 1998-12-24 2000-07-06 Astrazeneca Ab Composes de pyrimidine
WO2001064654A1 (fr) * 2000-03-01 2001-09-07 Astrazeneca Ab Composes de pyrimidine
US20040063705A1 (en) * 2001-08-22 2004-04-01 Jean-Christophe Harmange Substituted pyrimidinyl derivatives and methods of use
WO2003066601A1 (fr) * 2002-02-08 2003-08-14 Smithkline Beecham Corporation Composes de pyrimidine
WO2003078404A1 (fr) * 2002-03-15 2003-09-25 Novartis Ag Derives de pyrimidine
WO2005013996A2 (fr) * 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. Composes de 2,4-pyrimidinediamine et leurs utilisations comme agents antiproliferants
WO2005026130A1 (fr) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines utiles dans le traitement de troubles proliferatifs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EL-KERDAWY M M ET AL: "2,4-BIS (SUBSTITUTED)-5-NITROPYRIMIDINES OF EXPECTED DIURETIC ACTION", EGYPTIAN JOURNAL OF CHEMISTRY, CAIRO, EG, vol. 29, no. 2, 1986, pages 247 - 251, XP000999986, ISSN: 0449-2285 *
GHOSH D: "2,4-BIS(ARYLAMINO)-6-METHYL PYRIMIDINES AS ANTIMICROBIAL AGENTS", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, THE INDIAN CHEMICAL SOCIETY, CALCUTTA, IN, vol. 58, no. 5, May 1981 (1981-05-01), pages 512 - 513, XP000918018, ISSN: 0019-4522 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9266912B2 (en) 2005-01-19 2016-02-23 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8785437B2 (en) 2005-01-19 2014-07-22 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7989448B2 (en) 2005-01-19 2011-08-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8476263B2 (en) 2005-01-19 2013-07-02 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211888B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9532998B2 (en) 2005-01-19 2017-01-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8211889B2 (en) 2005-01-19 2012-07-03 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US9248190B2 (en) 2005-06-08 2016-02-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US9593082B2 (en) 2005-06-08 2017-03-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway

Also Published As

Publication number Publication date
EA200800285A1 (ru) 2008-08-29
US20080269170A1 (en) 2008-10-30
NO20080456L (no) 2008-03-04
NZ564872A (en) 2010-01-29
CR9602A (es) 2008-03-05
BRPI0613452A2 (pt) 2011-01-11
MX2008000574A (es) 2008-03-14
KR20080027832A (ko) 2008-03-28
WO2007006926A2 (fr) 2007-01-18
IL188494A0 (en) 2008-04-13
TNSN07471A1 (en) 2009-03-17
CA2614597A1 (fr) 2007-01-18
MA29649B1 (fr) 2008-07-01
AU2006268531A1 (en) 2007-01-18
ECSP078064A (es) 2008-01-23
JP2009501711A (ja) 2009-01-22
EP1904479A2 (fr) 2008-04-02

Similar Documents

Publication Publication Date Title
WO2007006926A3 (fr) Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
WO2008099072A3 (fr) Nouveaux derives de 2, 4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
JO2935B1 (en) 6- Tertiary azulo pyridazine sulfanil benzothiazole and benzimidazole derivatives, method of preparation, use as pharmaceutical products, pharmaceutical compositions and new use in particular as met inhibitors (methionine)
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
HK1113790A1 (en) Selurampanel
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20062644L (no) DPP-IV inhibitorer
HRP20090076A2 (en) Antiviral phosphinate compounds
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
WO2008081096A3 (fr) Derives quinolinyliques, leur procede de preparation. les compositions pharmaceutiques qui les contiennent et leur utilisation comme agents hypoglycemiants et hypoli pemiants
NO20055688L (no) Organiske forbindelser
TW200612936A (en) Indole derivatives
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
WO2006100081A3 (fr) Derives d'indoxyle substitues, medicaments les contenant et leur utilisation
CY1106857T1 (el) Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
NO20054787L (no) Indenderivater som farmasotiske midler
TW200745122A (en) New compounds I
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
HK1154777A1 (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: CR2007-009602

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: DZP2007000809

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 4999/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006778795

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 188494

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 564872

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 0800691

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2006268531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2614597

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 08001557

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2008520910

Country of ref document: JP

Ref document number: 2008010051

Country of ref document: EG

Ref document number: 12008500077

Country of ref document: PH

Ref document number: 1020087000779

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/000574

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 1200800261

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2006268531

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006268531

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200800285

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200680029511.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006778795

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0613452

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080111